Levosimendan for acute heart failure - horizon scanning review
NHSC
Record ID 32004000884
English
Authors' objectives:
This study aims to summarise the currently available evidence on levosimendan for acute heart failure.
Authors' recommendations:
Levosimendan (Simdax) is a short-term add on treatment for acutely decompensated heart failure that is in phase III clinical trials. Clinical trials published to date have found that patients given levosimendan experienced a positive haemodynamic benefit, and a lower risk of death and worsening heart failure than patients receiving placebo. Mortality was lower at 14 days (11.7% versus 19.6%; hazard ratio 0.56, 95% CI 0.33-0.95, p=0.031).
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Heart Failure
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.